Solid Biosciences Inc. has received FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations for SGT-212 to treat Friedreich’s ataxia (FA). The Phase 1b FALCON trial has dosed its first participant, with initial data expected in H2 2026. SGT-212 is a gene therapy targeting FA’s neurologic, cardiac, and systemic manifestations. The FALCON trial aims to evaluate the safety and tolerability of SGT-212 in participants with FA and cardiac hypertrophy. FA is a rare, life-threatening disease with no current cure, impacting around 5,000 people in the US and 15,000 in Europe. Solid Biosciences is dedicated to developing precision genetic medicines for rare neuromuscular and cardiac diseases.

Read more at GlobeNewswire: Solid Biosciences Receives FDA Orphan Drug Designation for